Revenue · 2023–2025
Monte Rosa Therapeutics revenue
$124M+63.5% · FY2025
Monte Rosa Therapeutics (GLUE) reported $124M in revenue for fiscal 2025, +63.5% year on year.
Revenue — Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026
Revenue at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Monte Rosa Therapeutics revenue |url=https://companiesranked.com/en/company/monte-rosa-therapeutics/revenue |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Monte Rosa Therapeutics revenue. CompaniesRanked. https://companiesranked.com/en/company/monte-rosa-therapeutics/revenueBibTeX
@misc{companiesranked-en-company-monte-rosa-therapeutics-revenue-2026,
author = {{CompaniesRanked}},
title = {{Monte Rosa Therapeutics revenue}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/monte-rosa-therapeutics/revenue}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-109360 · March 17, 2026
{{cite web |title=Monte Rosa Therapeutics revenue — 10-K (0001193125-26-109360) |url=https://www.sec.gov/Archives/edgar/data/1826457/000119312526109360/glue-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-17}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.